CHMA NASDAQ
Chiasma, Inc.
1W: -9.4%
1M: -14.0%
3M: -5.5%
1Y: -20.5%
3Y: +168.6%
5Y: +38.2%
$3.76
Last traded 2021-08-05 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range3.76-4.1
Volume8,196,718
Avg Volume996,380
Beta1.26
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORaj Kannan
Employees84
SectorHealthcare
IndustryBiotechnology
IPO Date2015-07-16
Websitechiasma.com
140 Kendrick Street, Building C East
Needham, MA 02451
US
Needham, MA 02451
US
16179285300
About Chiasma, Inc.
Chiasma, Inc. is a biopharmaceutical company in the advanced stages of clinical development, specializing in oral drug formulations. The company utilizes its Transient Permeability Enhancer (TPE) technology platform to develop treatments for rare and serious chronic conditions on a global scale. A key product in its pipeline is MYCAPSSA, an oral octreotide capsule currently in Phase III clinical trials. MYCAPSSA is intended for adult patients diagnosed with acromegaly, a disorder marked by the overproduction of growth hormone in the body. Founded in 2001, Chiasma, Inc. is headquartered in Needham, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| STONEPINE CAPITAL, L | D-Return | 6,770,000 | — | 2021-08-05 |
| LUDLAM WILLIAM | D-Return | 14,531 | $9.93 | 2021-08-05 |
| LUDLAM WILLIAM | D-Return | 11,799 | — | 2021-08-05 |
| LUDLAM WILLIAM | D-Return | 45,916 | $28.40 | 2021-08-05 |
| LUDLAM WILLIAM | D-Return | 74,997 | $2.60 | 2021-08-05 |